Local Anesthesia Pain: A Predictor of Post-Cesarean Pain? Pain during infiltration of local anesthesia is linked to a higher intensity of pain 24 hours after cesarean delivery and lower global health ...

Medscape UK -- with comprehensive coverage of the NHS, UK & NICE guidelines, drugs alerts, and the latest medical research of interest to doctors in England, Scotland, Wales, and Northern Ireland.

Psoriasis: Presentation, Imitators, and Treatment Psoriasis is a disfiguring and often painful skin condition that affects an estimated 125 million people worldwide. Know the facts about this ...

Clinicians caution that while the app flags possible anemia, definitive diagnosis requires lab testing, patient history and ...

Kennedy Replaces Fired US CDC Panel Members, Includes Anti-vaccine Proponents U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...

Local Anesthesia Pain: A Predictor of Post-Cesarean Pain? Pain during infiltration of local anesthesia is linked to a higher intensity of pain 24 hours after cesarean delivery and lower global health ...

Can Dose Spacing of IL-17i Maintain Efficacy in Psoriasis? IL-17 inhibitors secukinumab and brodalumab demonstrate similar efficacy in patients with psoriasis for up to a year after dose spacing, ...

Canada can build successful diabetes prevention and remission programs across the country by learning from England and ...

Acute dacryocystitis is common in women, and the risk for the condition rises with age, especially in those with primary acquired nasolacrimal duct obstruction.

Ovarian Cancer: 5 Things to Know Early symptoms of ovarian cancer can be vague and nonspecific, but it is one of the leading causes of gynecologic cancer deaths. Keep alert with these five things to ...

Without Measles Herd Immunity, Vulnerable Kids Are at Risk With a 97% effective vaccine, 3% of children rely on ‘halos’ of herd immunity protection, clinicians say. Declining vaccination rates will ...

ASCO 2025 Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly refractory ...